44,100 Shares in Solventum Corporation $SOLV Bought by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd acquired 44,100 Solventum shares during the second quarter, valued at approximately $3.4 million. Several other institutional investors also initiated or increased positions.
• Solventum reported quarterly EPS of $2.55, beating estimates of $1.91, while revenue reached $2.21 billion and rose 2.2% year over year. The company reaffirmed fiscal 2026 EPS guidance of $7.10–$7.20.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $92.80; recent targets range as high as $105.

WINTON GROUP Ltd bought a new stake in Solventum Corporation (NYSE:SOLV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 44,100 shares of the company's stock, valued at approximately $3,402,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. United Services Automobile Association acquired a new position in Solventum in the first quarter worth approximately $239,000. Woodline Partners LP lifted its stake in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company's stock valued at $888,000 after acquiring an additional 3,377 shares during the last quarter. Intech Investment Management LLC grew its position in Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock worth $1,268,000 after acquiring an additional 10,425 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Solventum by 5.8% during the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company's stock worth $19,546,000 after purchasing an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Solventum in the 2nd quarter valued at $766,000.

Solventum Trading Down 0.3%

Shares of SOLV stock opened at $87.43 on Friday. The firm has a market capitalization of $14.88 billion, a P/E ratio of 10.69, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $94.16. The firm's fifty day simple moving average is $85.15 and its 200 day simple moving average is $76.55. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business's revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, sell-side analysts predict that Solventum Corporation will post 7.22 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on SOLV. BTIG Research increased their price target on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Stifel Nicolaus upped their price objective on shares of Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. BMO Capital Markets began coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a "market perform" rating and a $81.00 target price on the stock. Wedbush lifted their target price on shares of Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Finally, Piper Sandler boosted their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $92.80.

Solventum Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.